Sugi Predict

Sugi Predict / Compounds / SCHEMBL2584005

SCHEMBL2584005

SCHEMBL2584005

Cc1cn2nc(Cl)cc(N3CCOCC3)c2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 5/20 0.53
▸ KMT2A Q03164 4/20 0.41
▸ SMPD3 Q9NY59 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ NCF1 P14598 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP7 P55210 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CRHR1 P34998 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2575429 0.87 SMPD3 (0.52) PDE10AKMT2ASMPD3NCF1MEN1
SCHEMBL20373322 0.87 SMPD3 (0.43) PDE10AKMT2ASMPD3NCF1MEN1
SCHEMBL2577886 0.83 PDE10A (0.50) PDE10AKMT2ASMPD3HSD17B10KDM4E
SCHEMBL13506188 0.83 PDE10A (0.48) PDE10AKMT2ASMPD3POLBKDM4E
SCHEMBL16283853 0.81 PDE10A (0.52) PDE10AKMT2ASMPD3KDM4ETSHR
SCHEMBL2587774 0.80 PDE10A (0.67) PDE10AKMT2ANCF1CYP1A2CYP2D6
SCHEMBL2586042 0.80 CNR2 (0.44) PDE10AKMT2ASMPD3NCF1CASP1
SCHEMBL16278744 0.80 PDE10A (0.59) PDE10AKMT2ACYP1A2CYP2D6MAPT
SCHEMBL12637479 0.78 PDE10A (0.59) PDE10AKMT2ANCF1HSD17B10KDM4E
SCHEMBL31519208 0.78 PDE10A (0.50) PDE10AKMT2AMEN1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4472968-A1 INHIBITORS OF RAF KINASES PIERRE FABRE MEDICAMENT (FR) 2024-12-11 — — EP disclosed
CN-118974036-A Inhibitors of RAF kinase 皮埃尔法布雷医药公司 2024-11-15 — — CN disclosed
US-20240182467-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2024-06-06 — — US disclosed
US-11814384-B2 Inhibtors of Raf kinases KINNATE BIOPHARMA INC. (US) 2023-11-14 — — US disclosed
US-20230303566-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2023-09-28 — — US disclosed
WO-2023150681-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2023-08-10 — — WO disclosed
EP-2493889-B1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-06 — — EP disclosed
EP-2493889-B1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-06 — — EP disclosed
US-9550784-B2 Inhibitors of phosphodiesterase 10 enzyme Beerse Pharmaceutica NV (BE) 2017-01-24 — — US disclosed
US-9550784-B2 Inhibitors of phosphodiesterase 10 enzyme Beerse Pharmaceutica NV (BE) 2017-01-24 — — US disclosed
US-20140364413-A1 PDE 10a Inhibitors for the Treatment of Type II Diabetes JANSSEN PHARMACEUTICA, NV (BE) 2014-12-11 — — US disclosed
US-8716282-B2 Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-05-06 — — US disclosed
WO-2014009305-A1 INHIBITORS OF PHOSPHODIESTERASE 10 ENZYME JANSSEN PHARMACEUTICA NV (BE) 2014-01-16 — — WO disclosed
US-20120220581-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN-CILAG, S.A. (ES) 2012-08-30 — — US disclosed
US-20120220581-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN-CILAG, S.A. (ES) 2012-08-30 — — US disclosed
US-20120220581-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN-CILAG, S.A. (ES) 2012-08-30 — — US disclosed
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PASTOR-FERNANDEZ JOAQUIN 2011-11-03 — — US disclosed
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PASTOR-FERNANDEZ JOAQUIN 2011-11-03 — — US disclosed
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PASTOR-FERNANDEZ JOAQUIN 2011-11-03 — — US disclosed
WO-2011051342-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364413-A1 PDE 10a Inhibitors for the Treatment of Type II Diabetes PDE2A, PDE3B, PDE3A PDE10A 9/4885KMT2A 1978/4885SMPD3 66/4885
US-20240182467-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF PDE10A 3310/4885KMT2A 1631/4885SMPD3 1673/4885
US-20230303566-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF PDE10A 3310/4885KMT2A 1631/4885SMPD3 1673/4885
US-20120220581-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PDE12, PDE10A, PDE5A PDE10A 2/4885KMT2A 1532/4885SMPD3 64/4885
US-11814384-B2 Inhibtors of Raf kinases RAF1, BRAF, ARAF PDE10A 3476/4885KMT2A 2824/4885SMPD3 3163/4885
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PDE12, PDE10A, PDE5A PDE10A 2/4885KMT2A 1532/4885SMPD3 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.